Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Blog

Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.

Page 4

Explainer

Tirzepatide Before an Endocrine Crisis

A case linked first-dose tirzepatide timing with a probable pheochromocytoma crisis, but tumor confirmation and drug causality remained unresolved.

14 Nov 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

Can Wegovy Affect an Alcohol Interlock?

A single Wegovy case report proposes a ketone-to-isopropanol route for disputed alcohol interlock results, but lacks chemical confirmation.

14 Nov 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

Calcitonin During Tirzepatide Therapy

A 76-person observational study found a small early calcitonin rise during tirzepatide therapy, but only two threshold events limited prediction.

13 Nov 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

GLP-1 review maps field without new data

A new GLP-1 review explains physiology and drug development but enrolls no participants and reports no original outcomes.

13 Nov 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

GLP-1 Review Maps PAD Evidence

A 2026 clinical review reports no new trial, while mapping semaglutide walking data and the weaker evidence on major limb events.

13 Nov 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

GLP1R Variants and Weight Loss Response

Rare GLP1R variants were linked to less weight loss with semaglutide, while a small tirzepatide carrier group had a near-normal response.

13 Nov 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

SOUL recurrent events: oral semaglutide

A secondary SOUL analysis counted first and later cardiovascular events. We separate its total-event result from the parent trial's primary endpoint.

13 Nov 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

Semaglutide in Youths With Autism

A retrospective cohort linked semaglutide with greater weight reductions in youths with autism and obesity, but only 20 received treatment.

13 Nov 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

Tirzepatide, Saliva and Complete Dentures

A 2026 letter raises a denture-saliva question but reports no participants, salivary measures, or clinical denture outcomes.

13 Nov 2026 · PeptideMethods Editorial Team · 6 min read
Trial readouts

Resistance Exercise With Tirzepatide

A 40-week randomized trial found that supervised resistance exercise reduced lean soft tissue loss and improved strength during tirzepatide treatment.

13 Nov 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

Tirzepatide Weight Response in Practice

A retrospective cohort found different tirzepatide weight trajectories by diabetes status, but prior GLP-1 treatment complicated the comparison.

13 Nov 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

Trevogrumab Preserved Lean Mass in COURAGE

A phase 2 trial found less lean-mass loss with trevogrumab during semaglutide treatment, while the garetosmab combination raised safety concerns.

13 Nov 2026 · PeptideMethods Editorial Team · 5 min read